Fertility-Sparing Treatment for Early-Stage Cervical Cancer ≥ 2 cm: A Problem with a Thousand Nuances—A Systematic Review of Oncological Outcomes

Carlo Ronsini, MD1, Maria Cristina Solazzo, MD1, Nicolò Bizzarri, MD2, Domenico Ambrosio, MD1, Marco La Verde, MD1, Marco Torella, MD1, Raffaela Maria Carotenuto, MD1, Luigi Cobellis, MD1, Nicola Colacurci, MD1, and Pasquale De Franciscis, MD1

1Department of Woman, Child and General and Specialized Surgery, University of Campania “Luigi Vanvitelli”, Naples, Italy; 2Unit of Gynecologic Oncology, Department of Woman, Child and Public Health, A. Gemelli, IRCCS, University Hospital Foundation, Rome, Italy

ABSTRACT

Background. Fertility-sparing treatments (FSTs) have played a crucial role in the management of early-stage cervical cancer (ECC). The guidelines have recognized various approaches, depending on the tumor stage and other risk factors such as histotype and lymphovascular positivity. Much more debate has centered around the boundary within which these treatments should be considered. Indeed, these are methods to be reserved for ECC, but tumor size may represent the most significant limitation. In particular, there is no consensus on the strategy to be adopted in the case of ECC ≥ 2 cm. Therefore, this systematic review was to collect the literature evidence regarding the management of these patients.

Methods. Following the recommendations in the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement, we systematically searched the Pubmed and Scopus databases was conducted in April 2022, from the date of the first publication. We made no limitation on the country. We included all studies containing data on disease-free survival, overall survival, recurrence rate (RR), or complete response rate (CRR) to chemotherapy.

Results. Twenty-six studies fulfilled the inclusion criteria, and 691 patients were analyzed regarding FST. Surgery-based FST showed an RR of between 0 and 42.9%, which drops to 12.9% after excluding the vaginal or minimally invasive approaches. Furthermore, papers regarding FST based on the neoadjuvant chemotherapy (NACT) approach showed a CRR of between 21.4 and 84.5%, and an RR of between 0 and 22.2%

Conclusion. This paper focused on the significant heterogeneity present in the clinical management of FST of ECC ≥ 2 cm. Nevertheless, from an oncological point of view, approaches limited to the minimally invasive or vaginal techniques showed the highest RR. Vice versa, the lack of standardization of NACT schemes and the wealth of confounders to be attributed to the histological features of the tumor make it difficult, if not impossible, to set a standard of treatment.

Although the incidence of cervical cancer has shown a downward trend in recent decades, in Western countries the age of first pregnancy has shown an opposite trend, raising its threshold.1,2 This has resulted in a possible overlapping, making it increasingly common for patients to be diagnosed with early-stage cervical carcinoma (ECC) who have not yet completed their reproductive expectations. Therefore, fertility-sparing treatments (FSTs) have played a crucial role in patient management. The guidelines recognize various approaches,3,4 depending on the tumor stage and other risk factors such as histotype and lymphovascular positivity.5 Much more debate has centered around the boundary within which these treatments should be
considered. Indeed, these are methods to be reserved for ECC, but tumor size may represent the most significant limitation. In particular, there is no consensus on the strategy to be adopted in the case of ECC ≥ 2 cm. In fact, of the five possible principal FSTs (conization, vaginal trachelectomy, minimally invasive trachelectomy, abdominal trachelectomy, and neoadjuvant chemotherapy combined with conization or trachelectomy), there is evidence of the inadequacy of the vaginal trachelectomy approach described by Dargent. The minimally invasive and abdominal approaches should also be set aside in parallel with the valid evidence for traditional radical hysterectomy surgery. Conversely, there is no consensus on the gold standard between radical abdominal approaches and neoadjuvant chemotherapy (NACT). Many referral centers use opposing strategies, making this field an open debate. In addition, more confusion is related to the fact that tumors ≥ 2 cm in size are at higher risk of recurrence regardless of FST. FST should be considered a non-routine approach for the management of ECC and deserves further investigation. Therefore, this systematic review aims to collect all the literature evidence regarding the management of these patients.

MATERIAL AND METHODS

The methods for this study were specified a priori based on the recommendations in the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. We registered the review in the PROSPERO database for meta-analysis (protocol number CRD42022316650).

Search Method

We conducted a systematic search of the Pubmed and Scopus databases in April 2022, from the date of the first publication, for articles on oncological outcomes in FST of ECC ≥ 2 cm. The search was restricted to studies published in the English language, and no restrictions on country were made. Search imputes were ‘fertility sparing’ and ‘cervical neoplasm’.

Study Selection

Study selection was made independently by MCS and RC, and in the case of discrepancies, CRR decided on the inclusion/exclusion of the studies. Inclusion criteria were (1) studies that included patients with ECC > 2 cm; and (2) studies that reported at least one outcome of interest (overall survival [OS], disease-free survival [DFS], recurrence rate [RR], and complete response rate [CRR]). We excluded peer-reviewed articles, either if published originally, as well as non-original studies, preclinical trials, animal trials, abstract-only publications, and articles in a language other than English. If possible, the authors of studies that were only published as congress abstracts were contacted via email and asked to provide their data. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flowchart (Fig. 1) details the studies selected and the reasons for exclusion. All included studies were assessed regarding potential conflicts of interest.

Data Extraction

MCS and RC extracted the data for all relevant series and case reports, as well as data on tumor characteristics (size, stage, histological subtype, lymphovascular space invasion [LVSI] status, grading), surgical approach, morbidity, and oncological issues such as recurrences, deaths, RR, and CRR to chemotherapy treatment (CR). Where possible, data on positive or close margins (taken to be indicative of inadequate surgical treatment), deep stromal infiltration (expressed as a percentage of patients with stromal infiltration ≥ 50%), and the distance between the tumor and internal uterus orefix were extracted; however, this activity was hindered by different criteria across papers and a diffused lack of information.

Quality Assessment

We assessed the quality of the included studies using the Newcastle–Ottawa scale (NOS). This assessment scale uses three broad factors (selection, comparability, and exposure), with the scores ranging from 0 (lowest quality) to 8 (best quality). Two authors (MT and MLV) independently rated the quality of the studies and any disagreement was subsequently resolved by discussion or consultation with a third author (CR). The NOS is reported in the electronic supplementary material.

RESULTS

Study Characteristics

After the database search, 629 articles matched the search criteria. After removing records with no full text, duplicates, and articles with the wrong study design (e.g., reviews), 32 studies remained that met the eligibility criteria, of which 26 matched the inclusion criteria and were included in the systematic review. All of these studies were retrospective or prospective studies evaluating surgical approaches such as abdominal radical tracheectomy
(ART), laparoscopic radical trachelectomy (LRT), robotic radical trachelectomy (RRT), and vaginal radical trachelectomy (VRT), or NACT followed by minor surgery (conization or vaginal trachelectomy) or the other technique mentioned (Fig. 1). A few of these studies reported a comparison between two or more surgical approaches, and none of them reported a direct comparison between ART and NACT. Table 1 summarizes the country where the study was conducted, publication year, study design, International Federation of Gynecology and Obstetrics (FIGO) tumor stage, and number of participants.  

FIGO International Federation of Gynecology and Obstetrics The quality of all studies was assessed using the Newcastle–Ottawa scale. Overall, the publication years ranged from 1991 to 2019. 691 patients who underwent FST for ECC ≥ 2 cm were enrolled in this systematic review. The follow-up period ranged from 21 to 95 months on average.

Outcomes

A total of 691 patients were included in the review. Fourteen of the 26 selected studies presented data on surgical FST, while the remaining 12 studies reported on FST with the use of NACT. We summarized data from FSTs with upfront surgery and FSTs with an NACT approach.

Surgical Fertility-Sparing Treatment (FST) Outcomes

Cao et al. performed a retrospective comparison between vaginal and abdominal trachelectomy in ECC. Data on ECC ≥ 2 cm treated with ART or VRT...
subanalysis were reported for a total of 48 patients (24 ART vs. 24 VRT). In a mean follow-up period of 20 months, no recurrence occurred in the ART group and 5 in the VRT group (RR 21.3% for VRT).

Deng et al.\textsuperscript{13} reported a 3-year DFS and OS rate of 95.2% and 97.6%, respectively, in 45 patients treated with ART.

Guo et al.\textsuperscript{14} investigated the oncological safety of ART compared with radical hysterectomy. In a subanalysis of

\begin{table}
\small
\centering
\caption{Study characteristics}
\begin{tabular}{lllll}
\hline
References & Country & Study design & Study year & FIGO stage & No. of participants \\
\hline
Cao et al.\textsuperscript{11} & China & Prospective, case-control, multicentric study & 2003–2012 & IB1 > 2 cm\textsuperscript{a} & 48 \\
De Vincenzo et al.\textsuperscript{12} & Italy & Retrospective, observational, monocentric study & 2014–2018 & IB2 & 13 \\
Deng et al.\textsuperscript{13} & China & Retrospective, observational, monocentric study & – & IB1 > 2 cm\textsuperscript{a} & 45 \\
Guo et al.\textsuperscript{14} & China & Retrospective, observational, monocentric study & 2003–2016 & IB1 > 2 cm\textsuperscript{a} & 71 \\
Kim et al.\textsuperscript{15} & Korea & Retrospective, observational, monocentric study & 2004–2009 & IB1 > 2 cm\textsuperscript{a} & 32 \\
Lanowska et al.\textsuperscript{16} & Germany & Retrospective, observational, monocentric study & 2006–2013 & IB1 > 2 cm\textsuperscript{a} & 18 \\
Li et al.\textsuperscript{17} & China & Retrospective, observational, monocentric study & 2004–2010 & IB1 > 2 cm\textsuperscript{a} & 14 \\
Li et al.\textsuperscript{18} & China & Retrospective, observational, monocentric study & 2004–2017 & IB1 > 2 cm\textsuperscript{a} & 132 \\
Lintner et al.\textsuperscript{19} & Hungary & Retrospective, observational, multicentric study & 1999–2006 & IB1 > 2 cm\textsuperscript{a} & 31 \\
Lu et al.\textsuperscript{20} & China & Retrospective, observational, monocentric study & 2005–2012 & IB1 > 2 cm\textsuperscript{a} & 6 \\
Marchiole et al.\textsuperscript{21} & France & Retrospective, observational, monocentric study & 2007–2010 & IB–IIA > 2 cm\textsuperscript{a} & 7 \\
Marchiole et al.\textsuperscript{22} & France & Retrospective, observational, monocentric study & 2007–2017 & IB1 > 2 cm\textsuperscript{a} & 19 \\
Okugawa et al.\textsuperscript{23} & Japan & Retrospective, observational, monocentric study & 2001–2011 & IB1 > 2 cm\textsuperscript{a} & 77 \\
Pahisa et al.\textsuperscript{24} & Spain & Retrospective, observational, monocentric study & 1996–2007 & IB1 > 2 cm\textsuperscript{a} & 4 \\
Park et al.\textsuperscript{25} & Korea & Retrospective, observational, multicentric study & 2004–2012 & IB2\textsuperscript{a} & 29 \\
Plante et al.\textsuperscript{26} & Canada & Prospective, observational, monocentric study & 1991–2010 & IB1 > 2 cm\textsuperscript{a} & 14 \\
Rendón et al.\textsuperscript{27} & Colombia & Retrospective, observational, monocentric study & 2009–2019 & IB1 > 2 cm\textsuperscript{a} & 25 \\
Robova et al.\textsuperscript{28} & Czech Republic & Retrospective, observational, monocentric study & 2005–2013 & IB1 > 2 cm\textsuperscript{a} & 28 \\
Salihi et al.\textsuperscript{29} & Belgium & Retrospective, observational, monocentric study & 2004–2013 & IB1 > 2 cm\textsuperscript{a} & 5 \\
Slama et al.\textsuperscript{30} & Czech Republic & Retrospective, observational, monocentric study & 2009–2014 & IB1 > 2 cm\textsuperscript{a} & 9 \\
Tesfai et al.\textsuperscript{31} & Netherlands & Retrospective, observational, monocentric study & 2006–2018 & IB–IIA\textsuperscript{a} & 19 \\
Testa et al.\textsuperscript{32} & Italy & Retrospective, observational, multicentric study & 2003–2008 & IB1 > 2 cm\textsuperscript{a} & 6 \\
Ungár et al.\textsuperscript{33} & USA & Prospective, observational, monocentric study & 1997–2002 & IB1 > 2 cm\textsuperscript{a} & 10 \\
Vercellino et al.\textsuperscript{34} & Germany & Retrospective, observational, multicentric study & 2004–2011 & IB1 > 2 cm\textsuperscript{a} & 6 \\
Wethington et al.\textsuperscript{35} & USA & Retrospective, observational, monocentric study & 2001–2011 & IB1 > 2 cm\textsuperscript{a} & 29 \\
Zusterzeel et al.\textsuperscript{36} & Netherlands & Retrospective, observational, monocentric study & 2009–2018 & IB2 & 18 \\
\hline
\end{tabular}
\footnotesize
\textsuperscript{a}FIGO stage 2009
\end{table}
this trial, 71 patients with ECC 2–4 cm underwent ART, with three recurrences and two deaths (RR 5.6%).

In 2010, Kim et al.15 treated eight patients with LRT for a 2–4 cm ECC, and reported a case of recurrence and subsequent death after 12 months (RR 12.5%).

In 2011, Li et al.17 published data on 14 ECCs of 2–4 cm treated with ART, with no recurrence in 22.8 months of mean follow-up.

In 2019, Li et al.18 expanded the case series with 132 patients and a 56-month follow-up period, during which they reported 11 recurrences and 5 deaths (RR 8.3%).

Littner et al.19 reported on 31 patients with ECC ≥ 2 cm treated with ART plus pelvic lymphadenectomy (PLND), 14 of whom had tumors ≥ 4 cm. Histotypes considered included grassy cell and anaplastic. These authors reported a median follow-up period of 90 months, with four recurrences and two deaths (RR 12.9%).

In 2020, Okugawa et al.20 published a series of 125 VRTs preceded by laparoscopic PLND, of which 14 were patients with tumors ≥ 2 cm in size. Only one recurrence occurred (RR 25%), but 50% of the procedures were aborted and converted to radical hysterectomy because of intraoperative complications.

Park et al.21 treated 29 ECCs ≥ 2 cm with LRT and reported nine recurrences and one death (RR 31%).

In 2011, Marchiole et al.22 presented a series of seven patients with tumors < 2 cm and ≥ 2 cm. Seventy-seven patients with ECCs ≥ 2 cm treated with ART had only two episodes of recurrence and one death from disease (RR 2.6%).

Pahisa et al.23 described their experience with VRT in ECC. In their series, four patients had tumors ≥ 2 cm in size. Only one recurrence occurred (RR 25%), but 50% of the procedures were aborted and converted to radical hysterectomy because of intraoperative complications.

Park et al.24 treated 29 ECCs ≥ 2 cm with LRT and reported nine recurrences and one death (RR 31%).

In 2011, Plante et al.25 published a series of 125 VRTs preceded by laparoscopic PLND, of which 14 were patients with tumors ≥ 2 cm. Six cases of recurrence and two deaths were observed in this subanalysis (RR 42.9%).

A 2013 paper by Testa et al.30 described six cases of RT for ECCs > 2 cm—five squamous cell carcinomas and one adenocarcinoma with no episode of recurrence.

In a stratification of the data shown by Ungar et al.31 in 2005, data were obtained for 10 patients with tumors ≥ 2 cm undergoing ART + PLND who had no recurrence event in 47 months of median follow-up.

Finally, Wethington et al.32 published a case series of 29 patients with ECC ≥ 2 cm treated with both abdominal and laparoscopic trachelectomy as well as robotic trachelectomy. One case that underwent RRT showed the only recurrence in the series, a woman with a 3 cm tumor (RR 3.5%).

Overall, surgical FST techniques showed an RR of between 0 and 42.6%, with a median follow-up period of between 20 and 93 months. In contrast, the RR range was between 0 and 12.9% for ART alone. If we exclude papers that presented data related to special histotypes (other than squamous cell carcinoma, adenocarcinoma, and adenosquamous carcinoma), the RR was 0–8.3%. These results are summarized in Table 2.

Neoadjuvant Chemotherapy FST Outcomes

The paper by de Vincenzo et al.12 represents the earliest published observational study of NACT with three cycles of cisplatin and paclitaxel q21 in ECC ≥ 2 cm. Of the 13 eligible patients, 11 responded to treatment. Furthermore, this study has the highest rate of complete response reported to date (84.5%). One patient presented with stable disease and was treated with conventional standard radical surgery, however one patient died due to disease progression. A single recurrence was observed in the 11 treated patients, with a mean follow-up of 37 months (RR 15.4%).

Litner et al.26 reported on 31 patients with ECC ≥ 2 cm treated with two or three cycles of paclitaxel + ifosfamide + cisplatin followed by radical vaginal trachelectomy (RVT). Complete response was obtained in 50% of the cases and only one recurrence was observed in a mean follow-up period of 23 months (RR 5.5%).

Lu et al.27 successfully treated six women with ECC ≥ 2 cm with two cycles of bleomycin + cisplatin + mitomycin q21 followed by LRT. At a 66-month median follow-up period, no recurrence was observed.

In 2011, Marchiole et al.28 presented a series of seven patients treated with three or four cycles of cisplatin + paclitaxel + ifosfamide, with a complete response in 57% of cases and an RVT on completion. No recurrences were reported. The same group reported an update of the case series in 2018,22 increasing the number of patients to 19, adding as an alternative to previous chemotherapy three to five cycles of cisplatin + paclitaxel + epirubicin, with CRR increased to 63%, and a completion surgery with laparoscopic-assisted vaginal trachelectomy (LARVT). Only two recurrences (RR 10.5%) were reported in a median follow-up period of 22–79 months.

Rendon et al.29 reported on the experience of 25 patients treated with different chemotherapy regimens combined with conization or radical trachelectomy, either by the open or laparoscopic approach. Complete response was observed in 44% of patients, with an RR of 12%.

In 2014, Robova et al.30 published data on dose-dense NACT (two different types based on histotypes) using an interval of 10–14 days. A combination of cisplatin (75 mg/m²) and ifosfamide (2 g/m², maximal total dose 3 g) was used in squamous cell carcinoma, and cisplatin (75 mg/m²) plus doxorubicin (35 mg/m²) was used in all adenocarcinomas. After NACT, patients underwent ART or VRT. A complex response was preserved in 21.4% of cases, and the RR was 14.3%. 

| Author(s) | Patients | Tumors Size | ART or VRT | Follow-up | Recurrences | Deaths | RR |
|-----------|----------|-------------|------------|-----------|-------------|--------|-----|
| de Vincenzo | 13 | ≥ 2 cm | NACT | 37 months | 1 | 0 | 15.4% |
| Litner et al. | 31 | ≥ 2 cm | ART + PLND | 23 months | 0 | 1 | 5.5% |
| Lu et al. | 6 | ≥ 2 cm | LRT | 66 months | 0 | 0 | 63% |
| Marchiole et al. | 19 | ≥ 2 cm | ART + VRT | 22–79 months | 2 | 1 | 10.5% |
| Rendon et al. | 25 | ≥ 2 cm | ART or VRT | 22–79 months | 0 | 0 | 44% |

Details of the study by de Vincenzo et al.12 include:

- **Patient Eligibility**: Eligible patients were those with ECC ≥ 2 cm who presented to the clinic between January 2005 and December 2009.
- **Chemotherapy Regimen**: NACT consisted of three cycles of cisplatin (75 mg/m²) and paclitaxel (150 mg/m²), followed by radical vaginal trachelectomy (RVT) on completion.
- **Outcome Measures**: Complete response was observed in 84.5% of cases, with a median follow-up period of 37 months. Only one recurrence was observed in the 11 treated patients, with an RR of 15.4%.

The paper by Litner et al.26 includes:

- **Patient Eligibility**: Eligible patients were those with ECC ≥ 2 cm who presented to the clinic between January 2005 and December 2009.
- **Chemotherapy Regimen**: The regimen consisted of two cycles of paclitaxel (150 mg/m²) and ifosfamide (2 g/m²), followed by radical vaginal trachelectomy (RVT) on completion.
- **Outcome Measures**: Complete response was observed in 57% of cases, with a median follow-up period of 23 months. Only one recurrence was observed, with an RR of 5.5%.

The study by Lu et al.27 includes:

- **Patient Eligibility**: Eligible patients were those with ECC ≥ 2 cm who presented to the clinic between January 2005 and December 2009.
- **Chemotherapy Regimen**: The regimen consisted of two cycles of bleomycin (10 mg/m²), cisplatin (75 mg/m²), and mitomycin (10 mg/m²), followed by radical vaginal trachelectomy (RVT) on completion.
- **Outcome Measures**: Complete response was observed in 63% of cases, with a median follow-up period of 23 months. Only one recurrence was observed, with an RR of 5.5%.

The paper by Rendon et al.29 includes:

- **Patient Eligibility**: Eligible patients were those with ECC ≥ 2 cm who presented to the clinic between January 2005 and December 2009.
- **Chemotherapy Regimen**: The regimen consisted of three cycles of cisplatin (75 mg/m²) and paclitaxel (150 mg/m²), followed by radical vaginal trachelectomy (RVT) on completion.
- **Outcome Measures**: Complete response was observed in 44% of cases, with a median follow-up period of 22–79 months. Two recurrences were observed, with an RR of 10.5%.

The study by Robova et al.30 includes:

- **Patient Eligibility**: Eligible patients were those with ECC ≥ 2 cm who presented to the clinic between January 2005 and December 2009.
- **Chemotherapy Regimen**: The regimen consisted of two cycles of cisplatin (75 mg/m²) and paclitaxel (150 mg/m²), followed by radical vaginal trachelectomy (RVT) on completion.
- **Outcome Measures**: Complete response was observed in 21.4% of cases, with an RR of 14.3%.
| References   | No. of patients | Hystological subtype         | Tracheectomy | Lymphadenectomy | Stromal infiltration > 50% (%) | Recurrence | Death | Mean follow-up | Recurrence rate (%) |
|-------------|----------------|-------------------------------|--------------|-----------------|-------------------------------|------------|-------|---------------|---------------------|
| Cao et al. 11 | 48             | SCC, ADK                      | 24 ART/24 VRT | NR              | 4.17/4.17                     | 0/5        | NR    | 20            | 0/21.7              |
| Deng et al. 13 | 45             | SCC, ADK                      | ART          | PLND/PALND      | 0 (in recurrences)            | 2          | 1     | 61            | 4.4                 |
| Guo et al. 14 | 71             | SCC, ADK, ADS                 | ART          | SLN             | 20.3                          | 4          | 3     | 75.5          | 5.6                 |
| Kim et al. 15 | 8              | SCC, ADK                      | LRT          | PLND/PALND      | 100                           | 1          | 1     | 31            | 12.5                |
| Li et al. 16  | 14             | SCC, ADK, ASK                 | ART          | NR              | NR                            | 0          | 0     | 22.8          | 0                   |
| Li et al. 18  | 132            | SCC, ADK, ASK, Anaplastic,    | ART          | PLND            | NR                            | 11         | 5     | 56            | 8.3                 |
| Litner et al. 19 | 31            | SCC, ASK, ADK, Anaplastic,    | ART          | SLN             | NR                            | 2          | 1     | 72            | 2.6                 |
| Okugawa et al. 23 | 77            | SCC, ASK, ADK                 | ART          | SLN             | NR                            | 1          | 0     | NR            | 25                  |
| Pahisa et al. 24 | 4              | SCC, ADK                      | VRT          | NR              | NR                            | 1          | 0     | NR            | 25                  |
| Park et al. 25 | 29             | SCC, ASK, ADK                 | LRT          | PLND            | 27.8                          | 9          | 1     | 44            | 31                  |
| Plante et al. 26 | 14            | SCC, ADK                      | VRT          | PLND            | NR                            | 6          | 2     | 93            | 42.9                |
| Testa et al. 32 | 6              | SCC, ADK                      | ART          | PLND            | NR                            | 0          | 0     | 29.6          | 0                   |
| Ungar et al. 33 | 10            | SCC, ADK, glassy cell         | ART          | PLND            | NR                            | 0          | 0     | 47            | 0                   |
| Wethington et al. 35 | 29          | SCC, ADK, ASK                 | 22 ART/6 LRT/1 RRT | PLND | NR | 1 (RRT) | 0 | 44 | 3.5 |

NR not reported, SCC squamous cervical cancer, ADK cervical adenocarcinoma, ASK cervical adenosquamous carcinoma, ADS cervical adenosarcoma, PLND pelvic lymphadenectomy, PALND para-aortic lymphadenectomy, SLN sentinel lymph node, RRT robotic radical trachelectomy, ART abdominal radical trachelectomy, VRT vaginal radical trachelectomy, LRT laparoscopic radical trachelectomy
A subanalysis of the paper by Salihi et al.\textsuperscript{29} showed data from five patients with ECC \( \geq 2 \text{ cm} \)—one treated with three cycles of paclitaxel, ifosfamide and cisplatin, and four treated with three cycles of paclitaxel and carboplatin weekly. Of the five patients, three had a complete response, one treated with paclitaxel, ifosfamide and cisplatin had a partial response, and one patient had progression.

In 2016, Slama et al.\textsuperscript{30} reported data on nine patients treated with stroma. Ifosfamide 1.75 g/m\(^2\) in combination with cisplatin 75 mg/m\(^2\) was administered to patients with squamous cell cancers, while doxorubicin 35 mg/m\(^2\) or paclitaxel 75 mg/m\(^2\) in combination with cisplatin 75 mg/m\(^2\) was administered to patients with adenocarcinomas, both in ‘dose density’ (10–12 days) intervals. Two recurrences and one death were reported (RR 22.2%).

Tesfai et al.\textsuperscript{31} instead adopted an NACT regimen of six cycles of cisplatin and paclitaxel. Of the 19 patients treated, a complete response was observed in 26.3% of cases. All cases were completed with ART, and the RR was 15.8%.

Vercellino et al.\textsuperscript{34} published a paper in 2012 focusing on the role of lymphadenectomy as an assessment of the lymph node status of patients with ECC to be candidates for FST. Of the six patients with ECC \( \geq 2 \text{ cm} \), cisplatin + paclitaxel ± ifosfamide, followed by VRT, resulted in a 50% CRR, with no recurrence during the median 30-month follow-up period.

Finally, Zusterzeel et al.\textsuperscript{30} proposed a six-cycle scheme of carboplatin + paclitaxel weekly in 18 patients with FIGO stage IB2, achieving a CRR of 38.8% and an RR of 22.2%. Overall, in a median follow-up period of between 22 and 79 months, the application of NACT schemes resulted in an RR of between 0 and 22.2%. In addition, wide variability in CRs was observed (21.4–84.5%).

Finally, in the reviewed papers, there was no agreement or standardization in the technique of deepening lymph node status, with surgeries ranging from sentinel lymph node (SLN) to systematic pelvic lymphadenectomy (PLND) and para-aortic lymphadenectomy (PALND). These results are summarized in Table 3.

DISCUSSION

Selection of the ideal patient to be a candidate for FST is still the main problem in the management of ECC; however, women with tumors < 2 cm in size, younger than 40 years of age and desirous of offspring find FST feasible.\textsuperscript{3,4} The problem becomes bigger when the tumor size exceeds 2 cm. In a scenario in which FST is not represented by a single technique but by a combination of different approaches, tumors \( \geq 2 \text{ cm} \) is an area in which there is less concordance in the literature and less standardization of techniques.\textsuperscript{5} The scientific community comprises groups with a surgical-first approach and groups using NACT. A lack of standardization even for these two approaches makes clinical practice extremely heterogeneous. This situation is also due to another factor, i.e. tumor size is one of the main risk factors for patients with ECC but it is certainly not the only risk factor. There are several criteria to be considered to select a patient for FST. First, the assessment of lymph node status; only patients with negative lymph nodes can be assessed for FST.\textsuperscript{3,4} This observation implies that lymph node negativity should be ascertained before or during the procedure to allow the surgeon to abandon FST and change it into conventional surgery (radical hysterectomy). The methods used by various teams to establish lymph node negativity vary from imaging techniques alone to systematic pelvic and lumbar-aortic lymphadenectomy. It should be mentioned that tumors larger than 2 cm themselves represent a high-risk category for lymph node spread and therefore assessment of lymph node negativity could play a crucial role in patient selection. In the group of upfront surgery papers, with the exception of Cao et al.\textsuperscript{11}, Li et al.\textsuperscript{17}, Li et al.\textsuperscript{18}, and Pahisa et al.\textsuperscript{24}, whose papers do not report these data, all other papers used lymphadenectomy as a method of intraoperative lymph node assessment. The degrees of extension of the technique range from SLN to systematic pelvic and lumbar-aortic lymphadenectomy. However, this strategy has some limitations. The use of frozen section does not permit the characterization of micrometastases, which themselves represent an independent risk factor for recurrence.\textsuperscript{37,38} On the other hand, dividing the approach into two steps—first performing lymphadenectomy and then conservative surgery only on histologically proven lymph node-negative patients—could hypothetically increase the intraoperative difficulties due to tissue fibrosis, hypothetically increasing the morbidity of the techniques and their risk of abandonment.\textsuperscript{39,40} Unfortunately, in this situation of impasse, the approach to be used is completely left to the choice of the team. A future alternative could be represented by intraoperative amplification techniques to obtain information in frozen section about micrometastases,\textsuperscript{41,42} but to date does not represent a clinical standard. Vice versa, teams that prefer the use of NACT necessarily must resort to a prechemotherapy assessment of lymph node status. In these groups of patients, lymph node investigations range from SLN to lymphadenectomy. However, contrary to the purely surgical group, where lymphadenectomy may follow SLN, in these cases, the SLN alone may be useful to select patients but may not guarantee the patient the curative benefit related to lymphadenectomy.\textsuperscript{43–45} Moreover, patients undergoing NACT will complete their FST with surgical techniques that are as
| References | No. of patients | Hystological subtype | Lymph node assessment | Chemotherapy | Surgery | Complete response (%) | Stomal Infiltration > 50 (%) | Recurrence | Death | Mean follow-up | Recurrence rate (%) |
|------------|----------------|----------------------|-----------------------|--------------|---------|-----------------------|-----------------------------|------------|-------|----------------|--------------------|
| De Vincenzo et al. 12 | 13 | SCC, ADK | PLND/SLN | cisplatin + paclitaxel q21 | Cold-knife conization | 84.5 | NR | 2 | 1 | 37 | 15.4 |
| Lanowska et al. 16 | 18 | SCC, ADK, ASK | PLND/SLN | 2–3 cisplatin + paclitaxel + ifosfamide | VRT | 50 | NR | 1 | 0 | 23 | 5.5 |
| Lu et al. 20 | 6 | SCC | SLN | bleomycin + cisplatin + mitomycin q21 | LRT | NR | NR | 0 | 0 | 66 | 0 |
| Marchiole et al. 21 | 7 | SCC, ADK | PLND | 3–4 cisplatin + paclitaxel + ifosfamide | VRT | 57 | NR | 0 | 0 | 22 | 0 |
| Marchiole et al. 22 | 19 | SCC, ADK | PLND/SLN | 3–5 TIP (cisplatin + paclitaxel + ifosfamide) 3–5 TEP (cisplatin + paclitaxel + epirubicin) | LARVT | 63 | NR | 2 | 0 | 79 | 10.5 |
| Rendon et al. 27 | 25 | SCC, ADK | PLND/SLN | 3–6 range carboplatin/paclitaxel (32%), cisplatin/paclitaxel (28%), paclitaxel/ifosfamide/cisplatin (16%), paclitaxel/cisplatin/5-fluorouracil (12%), 5-fluorouracil/ifosfamide/cisplatin (8%), vincristine/bleomycin/cisplatin in one patient | (5) Cold-knife conization/ (11) ART/ (9) LRT | 44 | NR | 3 | 0 | 62 | 12 |
| Robova et al. 28 | 28 | SCC, ADK | PLND/SLN | 3 cisplatin + ifosfamide (SCC); cisplatin + doxorubicin (ADK) | ART/VRT | 21.4 | NR | 4 | 2 | 42 | 14.3 |
| Salhi et al. 29 | 5 | SCC, ADK | PLND | Cisplatin + paclitaxel + ifosfamide/carboplatin + paclitaxel weekly | Cold-knife conization | 64 | NR | 1 | 0 | 58 | 20 |
| Slama et al. 30 | 9 | SCC, ADK | SLN | 3 cisplatin+ ifosfamide (SCC); cisplatin + doxorubicin (ADK) | Needle conization/ simple vaginal trachelectomy | NR | NR | 2 | 1 | 23 | 22.2 |
| Tesfai et al. 31 | 19 | SCC, ADK, ADK with clear cell | PLND | 6 cisplatin + paclitaxel | ART | 26.3 | NR | 3 | 1 | 50 | 15.8 |
| Varcellino et al. 34 | 6 | SCC, ADK, ASK | PLND/PALND | 1 cisplatin + paclitaxel (16.6%); 2–3 cisplatin + paclitaxel + ifosfamide (83.4%) | VRT | 50 | NR | 0 | 0 | 30.6 | 0 |
| Zusterzeel et al. 36 | 18 | SCC, ADK | PLND | 6 cisplatin + paclitaxel | VRT | 38.8 | NR | 4 | 0 | 49.7 | 22.2 |

NR not reported, SCC squamous cervical cancer, ADK cervical adenocarcinoma, ASK cervical adenosquamous carcinoma, PLND pelvic lymphadenectomy, PALND para-aortic lymphadenectomy, SLN sentinel lymph node, VRT vaginal radical trachelectomy, LRT laparoscopic radical trachelectomy, LARVT laparoscopic-assisted vaginal trachelectomy, ART abdominal radical trachelectomy
minimally invasive as possible. The goal of this approach is to minimize surgical morbidity and improve fertility outcomes, which were not the subject of this review. However, regarding this group of patients, the great heterogeneity in the therapy schemes applied should be noted, which led to extremely variable CRRs (21.4–84.5%). This additional variable represents a confounding factor in determining the best FST approach for patients with ECC ≥ 2 cm. Similarly, it has been almost impossible to extract from the published papers the rationale for the surgical approach chosen in combination with NACT. No paper expressed how much this should be influenced by the response of the tumor to chemotherapy. Furthermore, we have no evidence of different behavior between chemo-sensitive and partially sensitive tumors. While the first category may represent an ideal candidate for FST, the other may be potentially considered with a degree of aggressiveness that exposes the patient to a higher risk of recurrence. In addition, it should be considered that papers reporting the combination of NACT and ART are likely to sum up the comorbidities of both. This combination could invalidate fertility outcomes without a real advantage in terms of RR, substantially overlapping with fertility-sparing surgery alone. Another ideological problem of patients’ selection is related to histological characteristics, primarily the size. There is no agreement in the reported studies of which is the method of choice for measuring tumor size (clinical evaluation, MRI,46 or the performance of conization before FST), and most of the papers in the literature do not report these data. Furthermore, the prognostic weight exerted by tumor size remains controversial. Recent scientific evidence has shown that lateral tumor extension (HZTE), marked as the maximum tumor diameter, is subordinate to stromal infiltration.47,48 This concept has recently led to a revision of the FIGO stage IA and IB definitions in 2019.49 In contrast, there is evidence in the literature that excessive extensions > 4 cm have proven negative outcomes.50 Unfortunately, none of the studies reported data on stromal infiltration. This may represent patient selection bias, grouping together patients with different risk profiles. Similarly, histologic characterization provides other key risk factors to guide our choice. First is the histotype. In the literature, there is agreement that squamous histotypes and adenocarcinomas are candidates for FST, while histologies such as grassy cell, anaplastic, or clear cell should be considered as types at high risk of recurrence6 and should therefore be reserved for FST only in highly selected cases.3 Not surprisingly, the paper by Litner et al.,19 the only study among FST surgical approaches to have enrolled patients with special histotypes, is also the study with the highest RR for ART (12.9%). Adenosquamous tumors, which are considered an intermediate aggressiveness and therefore more suitable for FST, must be considered a borderline indication of FST.51 Other fundamental histological factors are represented by grading52 and depth of infiltration.53 These factors represent an incognita that often becomes known only after FST, and may condition the choice for adjuvant treatment54 or abandonment of FST, because punch biopsy alone may not represent the entire tumor.55 Finally, a key prognostic factor that is often missed in the decision-making process for FST is LVSI.56,57 In the case of positive LVSI, it is theoretically possible to hypothesize a greater benefit of NACT approaches because of the systemic bonification that they guarantee, and therefore greater control regarding distant recurrences, of which they can and do represent an independent risk factor.58 For the reasons stated, it might be routinely advised to perform conization before FST, regardless of the strategy to be practiced, with the advantage of obtaining this histological information and decreasing tumor size.59 The lack of standardization of the concepts of ‘close margin’ and ideal length of residual healthy cervical tissue is a final confounding factor, with the distance varying in the case series between 0.5 and 1 cm. Most of the proposed works do not report these characteristics, making a vain attempt to weigh the risks related to the technique adopted. In this regard, the radicality of the surgical approach adopted in FST seems to be crucial in the RR for patients with ECC ≥ 2 cm. In 2016, a review published in Lancet Oncology5 disputed the role of VRT and simple trachelectomy in patients with tumors ≥ 2 cm in size. Our results agree, showing that the VRT approach has the highest RR (Cao et al.11, 21.7%; Pahisa et al.24, 25%; Plante et al.26, 42.9%). These figures are very different from the results attributed to ART, where the RR is at a maximum of 5.6% (Guo et al.14). On the other hand, minimally invasive techniques deserve a separate discussion, where the RR of laparoscopic approaches has a peak of 31% in the study by Park et al.25 This funding aligns with the current scientific evidence regarding the best surgical approach for radical hysterectomy in tumors ≥ 2 cm.8,60 Even if heterogeneity of the adopted therapy schemes and the completion surgeries makes a direct comparison almost impossible, the group of works on NACT FST showed, on average, higher RR (5.5–22.2%) compared with ART (0–12.9%). Moreover, the surgical approach could condition the pattern of recurrence. Centro-pelvic recurrences should be ascribed to defects in surgical technique, whereas distant recurrences could be attributable to intrinsic tumor characteristics or poor patient selection.61,62
Our opinion is that the strength of the study lies in its systematic nature and rigor of the research, which has extracted all the literature data on patients with ECC ≥ 2 cm. Similarly, this represents the main limitation of our paper, which aims to summarize data from extremely heterogeneous approaches that well reflect current clinical practice. In addition, this review represents a partial view of the problem of fertility preservation, focused mainly on oncological outcomes. Our research group is currently conducting a similar review focused on fertility outcomes (Prospero registration number CRD42022329253). However, it seems clear that greater standardization in the selection of patients is necessary, and the identification of different risk classes even within a pattern of patients, i.e. those with ECC ≥ 2 cm, is already considered at the extreme limits of acceptability of FST. The higher the patient’s inherent risk, the more attention should be paid by the clinician to the contextualization of the proposed clinical pathway. Therefore, it would be desirable to design clinical trials that prospectively minimize the bias related to tumor characteristics and not to the proposed FST.

CONCLUSION

Our paper focused on the significant heterogeneity present in the clinical management of FST of ECC ≥ 2 cm. Nevertheless, from an oncological point of view, approaches limited to the minimally invasive or vaginal techniques seem to show the highest RR. Vice versa, the lack of standardization of NACT schemes and the wealth of confounders to be attributed to the histological features of the tumor make it difficult, if not impossible, to set a standard of treatment. Further randomized clinical trials with clear patient selection criteria will be necessary to clarify the existing doubts.

AUTHOR CONTRIBUTIONS CR: Conceptualization, methodology, data curation, writing—original draft. MCS: Data curation, review and editing. NB: Data curation, review and editing. LC: Review and editing. NC: Review and editing. PDF: Review and editing, validation.

FUNDING Open access funding provided by Università degli Studi della Campania Luigi Vanvitelli within the CRUI-CARE Agreement.; Please verify relation to: Università degli Studi della Campania Luigi Vanvitelli; Open access funding provided by Università degli Studi della Campania Luigi Vanvitelli within the CRUI-CARE Agreement.

DISCLOSURE Carlo Ronsini, Maria Cristina Solazzo, Nicolò Bizzarro, Domenico Ambrosio, Marco La Verde, Marco Torella, Raffaele Maria Carotenuto, Luigi Cobellis, Nicola Colacurci, and Pasquale De Franciscis have no disclosures to declare.

Supplementary Information The online version contains supplementary material available at https://doi.org/10.1245/s10434-022-12436-w.

OPEN ACCESS This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

REFERENCES

1. Falcaro M, Castaño A, Ndale B, Checchi M, Soldan K, Lopez-Bernal J, Elliss-Brookes L, Sasieni P. The effects of the national HPV vaccination programme in England, UK, on cervical cancer and grade 3 cervical intraepithelial neoplasia incidence: a register-based observational study. Lancet. 2021;398(10316):2084–92. https://doi.org/10.1016/S0140-6736(21)02178-4.
2. du Fossé NA, van der Hoorn MP, van Lith JMM, le Cessie S, Lashley EEO. Advanced paternal age is associated with an increased risk of spontaneous miscarriage: a systematic review and meta-analysis. Hum Reprod Update. 2020;26(5):650–69. https://doi.org/10.1093/humupd/dmaa010.
3. Cibula D, Pötter R, Chiva L, Planchamp F, Avall-Lundqvist E, Cibula D, Raspolini M. The European Society of Gynaecological Oncology/European Society for Radiotherapy and Oncology/European Society of Pathology guidelines for the management of patients with cervical cancer. Int J Gynecol Cancer. 2018;28(4):641–55. https://doi.org/10.1097/IGC.0000000000001216.
4. Cervical Cancer, Version 3.2019. NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2019;17(1):64–84. https://doi.org/10.6004/jnccn.2019.0001.
5. Bentivegna E, Gouy S, Maulard A, Chargari C, Leary A, Morice P. Oncological outcomes after fertility-sparing surgery for cervical cancer: a systematic review. Lancet Oncol. 2016;17(6):e240–53. https://doi.org/10.1016/S1470-2045(16)30032-8.
6. Delgado G, Bundy B, Zaino R, Sevin BU, Creasman WT, Major F. Prospective surgical-pathological study of disease-free interval in patients with stage IB squamous cell carcinoma of the cervix: A Gynecologic Oncology Group study. Gynecol Oncol. 1990;38:352–7.
7. Covens A, Rosen B, Murphy J, et al. How important is removal of the parametrium at surgery for carcinoma of the cervix? Gynecol Oncol. 2002;84:145–9.
8. Ramirez PT, Frumovitz M, Pareja R, et al. Minimally invasive versus abdominal radical hysterectomy for cervical cancer. N Engl J Med. 2018;379:1895–904.
9. Moher D. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151:264. https://doi.org/10.7326/0003-4819-151-4-20090818-00135.
10. Kansagara D, O’Neill M, Nugent S, Freeman M, Low A, Kondo K, Elven C, Zakher B, Motu’apuka M, Paynter R, et al. [Table], Quality Assessment Criteria for Observational Studies, Based on the Newcastle-Ottawa Scale. (2017) https://www.ncbi.nlm.nih.gov/books/NBK476448/table/appc.t4/. Accessed 16 Aug 2021.
11. Cao DY, Yang JW, Wu XH, Chen YL, Li L, Liu KJ, Cui MH, Xie X, Wu YM, Kong BH, Zhu GH, Xiang Y, Lang JH, Shen K. China Gynecologic Oncology Group. Comparisons of vaginal and abdominal radical trachelectomy for early-stage cervical cancer: preliminary results of a multi-center research in China. *Br J Cancer*. 2013;109(11):2778–82. https://doi.org/10.1038/bjc.2013.656.

12. de Vincenzo R, Ricci C, Fanfani F, Gui B, Gallotta V, Fogatti A, Ferrandina G, Scambia G. Neoadjuvant chemotherapy followed by conization in stage IB2-IIA1 cervical cancer larger than 2 cm: a pilot study. *Fertil Steril*. 2021;115(1):148–56. https://doi.org/10.1016/j.fertnstert.2020.07.006.

13. Deng X, Zhang Y, Li D, Zhang X, Guo H, Wang F, Sheng X. Abdominal radical trachelectomy guided by sentinel lymph node biopsy for stage IIB cervical cancer with tumors ≥2 cm. *Onco-target*. 2017;8(2):3422–9. https://doi.org/10.18632/oncotarget.13788.

14. Guo J, Zhang Y, Chen X, Sun L, Chen K, Sheng X. Surgical and oncologic outcomes of radical abdominal trachelectomy versus hysterectomy for stage I A2-I B1 cervical cancer. *J Minim Invasive Gynecol*. 2019;26(3):484–91. https://doi.org/10.1016/j.jmig.2018.06.006.

15. Kim JH, Park JY, Kim DY, Kim YM, Kim YT, Nam JH. Fertility-sparing laparoscopic radical trachelectomy for young women with early stage cervical cancer. *BIOG*. 2010;117(3):340–7. https://doi.org/10.1111/j.1471-0528.2009.0446.x.

16. Lanowska M, Mangler M, Speiser D, Stockholdt C, Schneider A, Köhler C, Vasiljeva J, Al-Hakeem M, Vercellino GF. Radical vaginal trachelectomy after laparoscopic staging and neoadjuvant chemotherapy in women with early-stage cervical cancer over 2 cm: oncologic, fertility, and neonatal outcome in a series of 20 patients. *Int J Gynecol Cancer*. 2014;24(3):586–93. https://doi.org/10.1097/IGC.0000000000000080.

17. Li J, Li Z, Wang H, Zang R, Zhou Y, Ju X, Ke G, Wu X. Radical abdominal trachelectomy for cervical malignancies: surgical, oncological and fertility outcomes in 62 patients. *Gynecol Oncol*. 2011;121(3):565–70. https://doi.org/10.1016/j.ygyno.2011.01.032.

18. Li X, Li J, Jiang Z, Xia L, Ju X, Chen X, Wu X. Oncological results and recurrent risk factors following abdominal radical trachelectomy: an updated series of 333 patients. *BIOG*. 2013;126(9):1169–74. https://doi.org/10.1111/j.1471-0528.15621.

19. Limmer B, Saso S, Tarnai L, Novak Z, Palflaki L, Del Priore G, Smith Jr, Ungar L. Use of abdominal radical trachelectomy to treat cervical cancer greater than 2 cm in diameter. *Int J Gynecol Cancer*. 2013;23(6):1065–70. https://doi.org/10.1097/IGC.0b013e318295fb41.

20. Lu Q, Zhang Y, Wang S, Guo S, Guo H, Zhang Z, Liu C. Neoadjuvant intra-arterial chemotherapy followed by total laparoscopic radical trachelectomy in stage IB1 cervical cancer. *Fertil Steril*. 2014;101(3):812–7. https://doi.org/10.1016/j.fertnstert.2013.12.001.

21. Marchiolò P, Tigaud JD, Costantini S, Mammoliti S, Buenard A, Moran M, Mathevet P. Neoadjuvant chemotherapy and vaginal radical trachelectomy for fertility-sparing treatment in women affected by cervical cancer (FIGO stage Ib-IIA1). *Gynecol Oncol*. 2011;122(3):484–90. https://doi.org/10.1016/j.ygyno.2011.05.010.

22. Marchiolò P, Ferraioli D, Moran E, Mammoliti S, Tigaud JD, Beurrier F, Chopin N, Mathevet P. NACT and laparoscopic-assisted radical vaginal trachelectomy in young patients with large (2–5 cm) high risk cervical cancers: safety and obstetrical outcome. *Surg Oncol*. 2018;27(2):236–44. https://doi.org/10.1016/j.suronc.2018.04.006.

23. Okugawa K, Yahata H, Sonoda K, Ohgami T, Yasunaga M, Kaneki E, Kato K. Safety evaluation of abdominal trachelectomy in patients with cervical tumors ≥2 cm: a single-institution, retrospective analysis. *J Gynecol Oncol*. 2020;31(4):e41. https://doi.org/10.3802/jgo.2020.31.41.

24. Park J, Alonso I, Torne Á. Vaginal approaches to fertility-sparing surgery in invasive cervical cancer. *Gynecol Oncol*. 2008;110(3 Suppl 2):S29–32. https://doi.org/10.1016/j.ygyno.2008.05.005.

25. Park JY, Joo WD, Chang SJ, Kim DY, Kim JH, Kim YM, Kim YT, Nam JH. Long-term outcomes after fertility-sparing laparoscopic radical trachelectomy in young women with early-stage cervical cancer: an Asian Gynecologic Cancer Group (AGCG) study. *J Surg Oncol*. 2014;110(3):252–7. https://doi.org/10.1002/jso.23631.

26. Plante M, Gregoire J, Renaud MC, Roy M. The vaginal radical trachelectomy: an update of a series of 125 cases and 106 pregnancies. *Gynecol Oncol*. 2011;121(2):290–7. https://doi.org/10.1016/j.ygyno.2010.12.345.

27. Rendon GJ, Lopez Blanco A, Aragona A, Saadi JM, Di Guilmi J, Arub Eben C, Heredia Muñoz F, Pareja R. Oncological and obstetrical outcomes after neo-adjuvant chemotherapy followed by fertility-sparing surgery in patients with cervical cancer ≥2 cm. *Int J Gynecol Cancer*. 2021;31(3):462–7. https://doi.org/10.1136/ijgc-2020-002076.

28. Robova H, Halaska MJ, Pluta M, Skapa P, Matecha J, Lisy J, Rob L. Oncological and pregnancy outcomes after high-dose density neoadjuvant chemotherapy and fertility-sparing surgery in cervical cancer. *Gynecol Oncol*. 2014;135(2):213–6. https://doi.org/10.1016/j.ygyno.2014.08.021.

29. Salihí R, Leunen K, Van Limbergen E, Moerman P, Neven P, Vergote I. Neoadjuvant chemotherapy followed by large cone resection as fertility-sparing therapy in stage IB cervical cancer. *Gynecol Oncol*. 2015;139(3):447–51. https://doi.org/10.1016/j.ygyno.2015.05.043.

30. Slama J, Cerny A, Dusek L, Fischerova D, Zikan M, Kocian R, Germanova A, Cibula D. Results of less radical fertility-sparing procedures with omitted parametrectomy for cervical cancer: 5years of experience. *Gynecol Oncol*. 2016;142(3):401–4. https://doi.org/10.1016/j.ygyno.2016.07.008.

31. Tesfai FM, Krop JR, Gaarenstroom K, De Kroon C, Van Loenhout R, Smit V, Trimbos B, Nout RA, van Poelgeest MIE, Benhammam J. Fertility-sparing surgery of cervical cancer ≥2 cm. (International Federation of Gynecology and Obstetrics. 2009 stage IB1-IB3) after neoadjuvant chemotherapy. *Int J Gynecol Cancer*. 2020;30(1):115–21. https://doi.org/10.1136/ijgc-2019-000647.

32. Testa R, Ramirez PT, Ferreyra H, Saadi J, Franco G, Golsman M, Perrotta M. Abdominal radical trachelectomy: a safe and feasible option for fertility preservation in developing countries. *J Low Genit Tract Dis*. 2013;17(4):378–84. https://doi.org/10.1097/LGT.0b013e318272ce89.

33. Ungár L, Pálflávi L, Höggs S, Síklós P, Boyle DC, Del Priore G, Smith JR. Abdominal radical trachelectomy: a fertility-preserving option for women with early cervical cancer. *BIOG*. 2005;112(3):366–9. https://doi.org/10.1111/j.1471-0528.2004.00421.x.

34. Vercellino GF, Piek JM, Schneider A, Köhler C, Mangler M, Speiser D, Chiantera V. Laparoscopic lymph node dissection should be performed before fertility preserving treatment of patients with cervical cancer. *Gynecol Oncol*. 2012;126(3):325–9. https://doi.org/10.1016/j.ygyno.2012.05.033.

35. Wethington SL, Sonoda Y, Park KJ, Alektiar KM, Tew WP, Chi DS, Leitao MM Jr, Jewell EL, Barakat RR, Abu-Rustum NR. Expanding the indications for radical trachelectomy: a report on 29 patients with stage IB1 tumors measuring 2 to 4 centimeters.
Int J Gynecol Cancer. 2013;23(6):1092–8. https://doi.org/10.1097/IGC.0b013e318296034a.

36. Zusterzeel PLM, Aarts JWM, Pol FJM, Ottevanger PB, van Ham MAPC. Neoadjuvant chemotherapy followed by vaginal radical trachelectomy as fertility-preserving treatment for patients with FIGO 2018 stage IB2 cervical cancer. Oncologist. 2020;25(7):e1051–9. https://doi.org/10.1634/theoncologist.2020-0063.

37. Cibula D, McCluggage WG. Sentinel lymph node (SLN) concept in cervical cancer: Current limitations and unanswered questions. Gynecol Oncol. 2019;152(1):202–7. https://doi.org/10.1016/j.ygyno.2018.10.007.

38. Cibula D, Zikan M, Slama J, Fischerova D, Kocian R, Germainova A, Burgetova A, Dusek L, Dundr P, Gregova M, Nemejcova K. Risk of micrometastases in non-sentinel pelvic lymph nodes in cervical cancer. Gynecol Oncol. 2016;143(1):83–6. https://doi.org/10.1016/j.ygyno.2016.07.101.

39. Lv X, Chen L, Yu H, Zhang X, Yan D. Intra-operative frozen section analysis of common iliac lymph node metastases in patients with stage IB1 and IIA1 cervical cancer. Arch Gynecol Obstet. 2012;285(3):811–6. https://doi.org/10.1007/s00404-011-2038-z.

40. Diaz-Feijoo B, Franco S, Torn A, Benito V, Hernandez A, Lago V, Rovira A, Acosta U, Agusti N, Gil-Morenos A, SEGO Spain-GOG Group. Implications of extraperitoneal paraaortic lymphadenectomy to the left renal vein in locally advanced cervical cancer. A Spanish multicenter study. Gynecol Oncol. 2020;158(2):287–93. https://doi.org/10.1016/j.ygyno.2020.05.004.

41. Fanfani F, Monterossi G, Di Meo ML, La Fera E, Dell’Orto F, Gios A, Lamanna M, Ferrari D, Donati E, Peregò P, Restaino S, Carlo R, Zannoni GF, Landoni F, Scambia G, Buda A. Standard ultra-staging compared to one-step nucleic acid amplification for the detection of sentinel lymph node metastasis in endometrial cancer patients: a retrospective cohort comparison. Int J Gynecol Cancer. 2020;30:372–7.

42. Restaino S, Ronsini C, Finelli A, Perrone E, Scambia G, Fanfani F. Role of blue dye for sentinel lymph node detection in early endometrial cancer. Gynecol Surg. 2017;14(1):23. https://doi.org/10.1186/s11601-017-0264-0.

43. Chen C, Duan H, Zhang W, Zhao H, Wang L, Kang S, Lin L, Zhao W, Ni Y, Li D, Chen J, Fan H, Chen X, Bin X, Lang J, Liu P. Comparison of survival outcomes with or without Para-aortic lymphadenectomy in surgical patients with stage IB1-IA2 cervical cancer in China from 2004 to 2016. BMC Cancer. 2021;21(1):1091. https://doi.org/10.1186/s12885-021-02879-2.

44. Tsuruga T, Fujimoto A, Kawana K, Mori M, Hasumi Y, Kino N, Tomio K, Miura S, Tanaka M, Sone K, Miyamoto Y, Ikeda Y, Kojima S, Adachi K, Nagasaka K, Matsumoto Y, Arimoto T, Oda K, Nakagawa S, Horie K, Yasugi T, Koyota H, Osuga Y, Fuji T. Radical hysterectomy with or without para-aortic lymphadenectomy for patients with stage IB2, IIA2, and IBV cervical cancer: outcomes for a series of 308 patients. Int J Clin Oncol. 2016;21(2):359–66. https://doi.org/10.1007/s10147-015-0907-3.

45. Yan DD, Tang Q, Tu YQ, Chen JH, Lv XJ. A comprehensive analysis of the factors of positive pelvic lymph nodes on survival of cervical cancer patients with 2018 FIGO stage IIIC1p. J Cancer Res Clin Oncol. 2019;145(3):835–7. https://doi.org/10.1007/s00432-019-03850-w.

46. Bhatia N, Berek JS, Cuello Fredes M, Denny LA, Grenman S, Kauhanarute K, Kehoe ST, Konishi I, Olswary AB, Prat J, Sankaranarayanan R, Brierley J, Mutch D, Querleu D, Cibula D, Quinn M, Botha H, Sigurd L, Rice L, Ryu NS, Nghan H, Mainpia J, Andrijono A, Purwoto G, Maheshwari A, Bafna UD, Plante M, Natarajan J. Revised FIGO staging for carcinoma of the cervix uteri. Int J Gynaecol Obstet. 2019;145(1):129–35. https://doi.org/10.1016/j.ijgo.12749.

47. Di Donato V, Caruso G, Sassu CM, Santangelo B, Bogni G, Plotti F, Sorbi F, Peroniola G, Palaia I, Terrin G, Angioli R, Benedetti Panici P, Muzzi L. Fertility-sparing surgery for women with stage IB1 cervical cancer of 4 cm or larger: a systematic review. J Gynecol Oncol. 2021;32(6):e83. https://doi.org/10.3802/jig.2021.32.6.e83.

48. Ditto A, Martinelli F, Bogni G, Fischetti M, Di Donato V, Lorusso D, Raspagliesi F. Fertility-sparing surgery in early-stage cervical cancer patients: oncologic and reproductive outcomes. Int J Gynecol Cancer. 2015;25(3):493–7. https://doi.org/10.1097/IGC.0000000000000371.

49. Lin J, Albers AE, Qin J, Kaufmann AM. Prognostic significance of overexpressed p16INK4a in patients with cervical cancer: a meta-analysis. PLoS ONE. 2014;9(9):e106384. https://doi.org/10.1371/journal.pone.0106384.

50. Allam M, Feely C, Millan D, Nevin J, Davis J, Siddiqui N. Depth of cervical stromal invasion as a prognostic factor after radical surgery for early stage cervical cancer. Gynecol Oncol. 2004;93(3):637–41. https://doi.org/10.1016/j.ygyno.2004.02.029.

51. Bedetti Panici P, Muzii L. Fertility-sparing surgery for women with stage IB2 cervical carcinoma (ECA): a Gynecologic Oncology Group Study. J Gynecol Oncol. 2020;31(3):e105. https://doi.org/10.1007/s00432-020-03095-9.

52. Lin J, Albers AE, Qin J, Kaufmann AM. Prognostic significance of overexpressed p16INK4a in patients with cervical cancer: a meta-analysis. PLoS ONE. 2014;9(9):e106384. https://doi.org/10.1371/journal.pone.0106384.

53. Allam M, Feely C, Millan D, Nevin J, Davis J, Siddiqui N. Depth of cervical stromal invasion as a prognostic factor after radical surgery for early stage cervical cancer. Gynecol Oncol. 2004;93(3):637–41. https://doi.org/10.1016/j.ygyno.2004.02.029.

54. Sedlis A, Bundy BN, Rotman MJ, Lentz SS, Mudderspach LI, Zaino RJ. A randomized trial of pelvic radiation therapy versus no further therapy in selected patients with stage IB2 carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy: a Gynecologic Oncology Group Study. J Gynecol Oncol. 1999;73(2):177–83. https://doi.org/10.1006/gyno.1999.5387.

55. Cong Q, Song Y, Wang Q, Zhang H, Gao S, Du M, Xie F, Dong J, Feng H, Diao W, Zhu C, Sai L. A large retrospective study of 12714 cases of LEEP conization focusing on cervical cancer that colposcopy-directed biopsy failed to detect. Biomed Res Int. 2018;2018:5138232. https://doi.org/10.1155/2018/5138232.

56. Delgado G, Bundy B, Zaino R, Sevin BU, Creasman WT, Major F. Prospective surgical-pathological study of disease-free interval in patients with stage IB squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Gynecol Oncol. 1990;38(3):352–7. https://doi.org/10.1006/ongo.1990.30072-s.

57. Morice P, Piovesan P, Rey A, Atallah D, Haie-Meder C, Pautier P, Sideris L, Pome L, Duvallard P, Castaigne D. Prognostic value of lymphovascular space invasion determined with hematoxylin-eosin staining in early stage cervical carcinoma: results of a multivariate analysis. Ann Oncol. 2003;14(10):1511–7. https://doi.org/10.1093/annonc/mdg412.

58. Ronsini C, Anchora LP, Restaino S, Fedele C, Arciuolo D, Teodorico E, Bizzarri N, Zannoni GF, Ferrandina G, Scambia G, Fanfani F. The role of semiquantitative evaluation of lymphovascular space invasion in early stage cervical cancer patients.
